Inclusion Criteria:

1. Japanese male or female patients with T2DM treated with diet and exercise alone or with one hypoglycaemic drug other than glitazones.

2. HbA1c at screening (Visit 1)

   • For patients treated with 1 other oral antidiabetic drug: HbA1c between 6.5% and 9.0%.
   • For patients not treated with any antidiabetic drug: HbA1c between 7.0% and 10.0%.
3. Age betwen 20 and 70 years
4. Body mass index (BMI) between18.0 and 40.0 kg/m2
5. Signed and dated written informed consent before admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation.

Exclusion Criteria:

1. Antidiabetic treatment with insulin or glitazones within 3 months before obtaining informed consent or with more than 1 oral hypoglycaemic agent at the time of informed consent
2. Fasted blood glucose of >240 mg/dL (>13.3 mmol/L) or a randomly determined blood glucose level of >400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out period.
3. Myocardial infarction, stroke, or transient ischaemic attack within 6 months before informed consent.

4. Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and medically treated hypertension before the first administration such as

   • Renal insufficiency (calculated estimated glomerular filtration rate <60)
   • Cardiac insufficiency of NYHA II-IV or other known cardiovascular diseases including hypertension of >160/95 mmHg,
   • Neurological disorders (such as epilepsy) or psychiatric disorders
   • Acute or clinically relevant chronic infections (e.g., human immunodeficiency virus, hepatitis, repeated urogenital infections)
   • Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder

5. Patients under treatment with any concomitant medication except for the following drugs at the time of informed consent.:

   • Statins.
   • Antihypertensives (diuretics not allowed)
   • Beta-Blockers for BPH.
   • Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol